



## **STEPPING INTO LEADERSHIP: MODULE 7 ORIENTATION BEGINS**

This week, our Module 7: Leadership in Medicines Development students are diving into orientation! They're beginning their journey toward leadership in Medical Affairs and Medicines Development, exploring key principles, connecting with global peers, and learning from industry leaders. Through business cases, panels, lectures, and interactive forums, they're already putting leadership theory into practice.

 Discover more about Module 7: [Leadership in Medicines Development](#)

## **TABLE OF CONTENTS**

2026 CMD Cohort Applications Are Now Open • P. 2

---

Dr. Peter Stonier on the Global Fellowship in Medicines Development P. 3

---

Building Trust Through Diversity • P. 4

---

RNA: The Ancient Molecules Shaping Tomorrow's Medicines • P. 4

---

# APPLICATIONS ARE NOW OPEN FOR THE 2026 CMD PROGRAM COHORT!

Whether you're seeking the full Certification in Medicines Development or prefer to take **individual modules à la carte**, the CMD Program provides a flexible, globally recognized pathway to advance your career in medicines development.

 **Join professionals from more than 85 countries in shaping the future of pharmaceutical medicine.**

 **The 2026 CMD Program begins in January 2026**

## What Our Students Are Saying:

*"This group experience gave us practical tools we've already started using. It's made us better at hearing other people out, especially when they think differently. We've also become more intentional about how we approach decisions at work."*

— Elan Lutinger, Director of Oncology Scientific Communications, Pfizer (USA)

## Learn More:

<https://gmdpacademy.org/certification-programs/certification-in-medicines-development/>

## Apply Today:

<https://info.gmdpacademy.org/gmdpapplication>

## RECOGNIZING EXCELLENCE: DR. PETER STONIER ON THE GLOBAL FELLOWSHIP IN MEDICINES DEVELOPMENT

---



**This was really, really brought to life, the whole exercise of actually having within our organization a group of people who could be considered to be senior, experienced high achievers and people who would really set an example for younger people coming through and developing their careers.**

**Dr. Peter Stonier**

Co-Program Director, GMDP Academy

Innovation in pharmaceutical medicine depends not only on science, but also on the expertise and leadership of professionals shaping the field. The Global Fellowship in Medicines Development celebrates these leaders while fostering a global network of mentorship, collaboration, and professional advancement.

Dr. Peter Stonier, Co-Program Director, explains:

"Well, the Global Fellowship came about because we wanted to recognize, we wanted to have within the context of medicine's development and a professional body representing medicines development, a group of people who were considered to be senior and high achievers and people who were recognized as such amongst their peers within the world of medicines development."

Since its launch in 2020, the program has welcomed over 200 Fellows worldwide. Fellows actively contribute to the profession by mentoring, supporting professional associations, and engaging in the Academy's educational programs. Programs like the Certification in Medicines Development (CMD) help build the leadership skills, knowledge, and global connections that may one day lead to recognition as a Global Fellow.

 Watch the full interview [here](#)

# BUILDING TRUST THROUGH DIVERSITY: CMD STUDENTS REIMAGINE CLINICAL TRIALS

Diversity in clinical trials has long been a challenge, with women, ethnic minorities, and people from lower socioeconomic backgrounds often excluded — creating mistrust and gaps in healthcare outcomes.

CMD students from Europe and Asia tackled this issue in Module 3: Drug Discovery using Edward de Bono’s Six Thinking Hats, exploring multiple perspectives on inclusion.

- “Patients often feel fear, anger, or distrust when excluded from clinical research. To alleviate this, we must make information clear, build therapeutic relationships, and debunk misconceptions to restore confidence.” – William Greenwood, Pfizer (France)

Their solutions included AI recruitment, flexible trial designs, and community partnerships — all aimed at making trials more inclusive and trusted.



[🔗 Advance Your Career in Medicines Development](#)

Applications are open for the 2026 CMD Program, [apply now](#).

# RNA: THE ANCIENT MOLECULE SHAPING TOMORROW'S MEDICINES



RNA may be one of the oldest molecules in biology, yet it’s transforming medicine. Once proposed as the origin of life, RNA now powers mRNA vaccines, gene-targeted therapies, and other cutting-edge treatments.

Even today, the ribosome—the cell’s protein factory—relies on RNA at its core. RNA therapeutics are often faster and simpler to manufacture than protein-based drugs. Researchers are also exploring synthetic RNA systems and artificial ribozymes to create new diagnostics, molecular machines, and therapeutic platforms.

At GMDP Academy, RNA is woven throughout the CMD program—from drug discovery and clinical trials to regulatory affairs—preparing professionals to understand and contribute to RNA-based innovations in medicines development. [1-8] Read more [here](#).

# REFERENCES

1. Attwater, J., et al. (2025). Trinucleotide substrates under pH-freeze-thaw cycles enable exponential RNA replication. *Nature Chemistry*, 17(7), 1129–1137.
2. Costello, A., & Badran, A.H. (2021). Synthetic biological circuits within an orthogonal central dogma. *Trends in Biotechnology*, 39(1), 59–71.
3. Gidaro, T., & Servais, L. (2019). Nusinersen treatment of spinal muscular atrophy. *Developmental Medicine & Child Neurology*, 61(1), 19–24.
4. Lilley, D.M.J., & Huang, L. (2025). RNA catalysis moving towards metabolic reactions. *Trends in Biochemical Sciences*, 50(5), 417–424.
5. Saito, H. (2022). The RNA world ‘hypothesis.’ *Nature Reviews Molecular Cell Biology*, 23(9), 582.
6. Scheitl, C.P.M., et al. (2020). Site-specific RNA methylation by a methyltransferase ribozyme. *Nature*, 587(7835), 663–667.
7. Titze-de-Almeida, S.S., et al. (2020). Leading RNA interference therapeutics: Patisiran. *Molecular Diagnosis & Therapy*, 24(1), 49–59.
8. Zhu, Y., et al. (2022). RNA-based therapeutics: An overview and prospectus. *Cell Death & Disease*, 13(7), 644.

---

## Thanks for reading!

The GMDP Academy Newsletter is published twice monthly and is compiled by the following:

**Media Manager:** Whitney English

**Editorial Board:** Pravin Chopra, Jacob Coots

**Operations Office:** Amanda Schmitt, Gustavo Silva, Kit Vale

## CONTACT US:



420 Lexington Ave. Ste. 300  
New York, NY 10170

(332) 333-2438